Endocrine Abstracts

The use of RAI for remnant ablation, as adjuvant therapy or as treatment for recurrent or metastatic disease is undergoing a significant reappraisal, based on its questionable efficacy in various disease contexts. Until recently postoperative RAI treatment was given to all patients with thyroid cancer regardless of the pathological stage of the disease. Although its use for low risk forms of thyroid cancer has diminished, current indications for adjuvant RAI treatment are not ...

Our understanding of the genetic abnormalities associated with thyroid cancers has grown significantly over the past decade. Thus, papillary thyroid cancers (PTC) have non-overlapping activating mutations genes encoding the growth factor receptors RET or NTRK, the three isoforms of RAS, or of BRAF, which altogether are found in ~70% of cases. In addition, mutations of effectors in the phosphoinositol-3-kinase (PI3K) pathway are present at various stages of the disease, but in ...

James A Fagin, Memorial Sloan-Kettering Cancer Center, New York, USA. AbstractJames A. Fagin is Chief of the Endocrine Service and a Member of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center in New York, and a Professor of Medicine at Weill Medical College of Cornell University. He was formerly the James Heady Professor of Medicine and Director of the Division of Endocrinology and...

Objectives: BRAFV600E- anaplastic thyroid cancers (ATCs) show remarkable responses to dabrafenib and trametinib (dab/tram) an effect that may be in part immune-mediated. Murine BRAFV600E-ATCs regress upon BRAF inhibition. We find that recurrences are frequent and associated with loss of Mhc class II (MhcII) expression. Our goal was to investigate the mechanisms of loss of antigen presentation by tumor cells and whether this contributes to disease recurren...